ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
AbCellera Biologics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research fees | $3.90M | $8.12M | $7.68M | $8.82M | $6.64M | $4.07M | $4.77M | $6.29M | $5.45M | $9.77M | $8.74M | $6.41M | 96.3% | -41.2% |
| Licensing and royalty revenue | $149.00K | $191.00K | – | – | $10.45M | $167.00K | – | – | – | – | – | – | 3.7% | -98.6% |
| Royalty revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Licensing and royalty revenue | – | – | $36.17M | $138.00K | $10.45M | $167.00K | $282.00K | $218.00K | $370.00K | $180.00K | $185.00K | $186.00K | – | – |
| Milestone payments | – | – | $1.00M | $0 | $0 | – | $0 | $0 | $1.50M | $0 | $250.00K | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of AbCellera Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.